T. Rowe Price Associates’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.39B | Sell |
4,746,585
-2,699,600
| -36% | -$887M | 0.16% | 125 |
|
|
2025
Q4 | $2.61B | Buy |
7,446,185
+1,607,274
| +28% | +$543M | 0.28% | 66 |
|
|
2025
Q3 | $1.89B | Sell |
5,838,911
-2,246,294
| -28% | -$699M | 0.2% | 91 |
|
|
2025
Q2 | $3.14B | Sell |
8,085,205
-1,057,358
| -12% | -$425M | 0.36% | 48 |
|
|
2025
Q1 | $3.98B | Sell |
9,142,563
-1,475,499
| -14% | -$592M | 0.49% | 35 |
|
|
2024
Q4 | $3.92B | Buy |
10,618,062
+464,137
| +5% | +$194M | 0.45% | 37 |
|
|
2024
Q3 | $5.28B | Sell |
10,153,925
-1,492,601
| -13% | -$797M | 0.61% | 25 |
|
|
2024
Q2 | $6.31B | Sell |
11,646,526
-73,734
| -0.6% | -$39M | 0.76% | 14 |
|
|
2024
Q1 | $6.08B | Sell |
11,720,260
-203,333
| -2% | -$101M | 0.74% | 17 |
|
|
2023
Q4 | $5.62B | Sell |
11,923,593
-107,780
| -0.9% | -$49.8M | 0.76% | 18 |
|
|
2023
Q3 | $5.24B | Sell |
12,031,373
-70,184
| -0.6% | -$31.8M | 0.77% | 17 |
|
|
2023
Q2 | $5.38B | Sell |
12,101,557
-1,175,613
| -9% | -$542M | 0.75% | 19 |
|
|
2023
Q1 | $6.1B | Buy |
13,277,170
+551,614
| +4% | +$263M | 0.91% | 14 |
|
|
2022
Q4 | $6.53B | Buy |
12,725,556
+1,979,665
| +18% | +$1.01B | 1.05% | 11 |
|
|
2022
Q3 | $4.88B | Buy |
10,745,891
+1,290,134
| +14% | +$617M | 0.8% | 16 |
|
|
2022
Q2 | $4.56B | Buy |
9,455,757
+699,906
| +8% | +$346M | 0.58% | 27 |
|
|
2022
Q1 | $4.3B | Sell |
8,755,851
-1,047,018
| -11% | -$479M | 0.43% | 37 |
|
|
2021
Q4 | $4.54B | Sell |
9,802,869
-20,557
| -0.2% | -$8.65M | 0.41% | 40 |
|
|
2021
Q3 | $3.66B | Sell |
9,823,426
-2,376,773
| -19% | -$903M | 0.34% | 53 |
|
|
2021
Q2 | $4.66B | Sell |
12,200,199
-486,365
| -4% | -$186M | 0.43% | 38 |
|
|
2021
Q1 | $4.55B | Buy |
12,686,564
+715,968
| +6% | +$230M | 0.46% | 34 |
|
|
2020
Q4 | $3.84B | Sell |
11,970,596
-1,730,192
| -13% | -$531M | 0.39% | 52 |
|
|
2020
Q3 | $3.68B | Sell |
13,700,788
-507,264
| -4% | -$136M | 0.43% | 42 |
|
|
2020
Q2 | $3.74B | Buy |
14,208,052
+625,569
| +5% | +$167M | 0.47% | 41 |
|
|
2020
Q1 | $3.08B | Buy |
13,582,483
+2,066,343
| +18% | +$563M | 0.49% | 35 |
|
|
2019
Q4 | $3.48B | Sell |
11,516,140
-362,880
| -3% | -$99.9M | 0.45% | 42 |
|
|
2019
Q3 | $2.85B | Sell |
11,879,020
-5,077,178
| -30% | -$1.39B | 0.4% | 51 |
|
|
2019
Q2 | $4.79B | Sell |
16,956,198
-2,328,453
| -12% | -$636M | 0.67% | 23 |
|
|
2019
Q1 | $5.53B | Sell |
19,284,651
-451,762
| -2% | -$131M | 0.81% | 15 |
|
|
2018
Q4 | $5.18B | Buy |
19,736,413
+1,197,941
| +6% | +$329M | 0.88% | 14 |
|
|
2018
Q3 | $5.08B | Sell |
18,538,472
-35,669
| -0.2% | -$9.26M | 0.74% | 17 |
|
|
2018
Q2 | $4.42B | Buy |
18,574,141
+418,984
| +2% | +$97M | 0.68% | 22 |
|
|
2018
Q1 | $3.99B | Buy |
18,155,157
+1,285,990
| +8% | +$302M | 0.63% | 27 |
|
|
2017
Q4 | $3.8B | Buy |
16,869,167
+2,419,549
| +17% | +$515M | 0.62% | 26 |
|
|
2017
Q3 | $2.74B | Buy |
14,449,618
+903,197
| +7% | +$172M | 0.47% | 43 |
|
|
2017
Q2 | $2.55B | Buy |
13,546,421
+460,630
| +4% | +$82.8M | 0.46% | 43 |
|
|
2017
Q1 | $2.16B | Sell |
13,085,791
-691,953
| -5% | -$110M | 0.41% | 51 |
|
|
2016
Q4 | $1.98B | Sell |
13,777,744
-1,181,496
| -8% | -$158M | 0.39% | 56 |
|
|
2016
Q3 | $1.87B | Sell |
14,959,240
-5,785,576
| -28% | -$747M | 0.38% | 61 |
|
|
2016
Q2 | $2.72B | Sell |
20,744,816
-3,862,731
| -16% | -$529M | 0.58% | 31 |
|
|
2016
Q1 | $3.42B | Sell |
24,607,547
-1,233,148
| -5% | -$165M | 0.73% | 22 |
|
|
2015
Q4 | $3.6B | Buy |
25,840,695
+2,421,033
| +10% | +$334M | 0.76% | 21 |
|
|
2015
Q3 | $3.28B | Buy |
23,419,662
+7,748,867
| +49% | +$1.16B | 0.73% | 22 |
|
|
2015
Q2 | $2.57B | Buy |
15,670,795
+4,104,738
| +35% | +$656M | 0.53% | 37 |
|
|
2015
Q1 | $1.79B | Buy |
11,566,057
+6,343,303
| +121% | +$903M | 0.37% | 59 |
|
|
2014
Q4 | $656M | Buy |
5,222,754
+306,508
| +6% | +$37.9M | 0.14% | 187 |
|
|
2014
Q3 | $588M | Buy |
4,916,246
+802,496
| +20% | +$92M | 0.13% | 190 |
|
|
2014
Q2 | $443M | Buy |
4,113,750
+125,822
| +3% | +$13M | 0.1% | 248 |
|
|
2014
Q1 | $397M | Sell |
3,987,928
-1,249,527
| -24% | -$113M | 0.09% | 265 |
|
|
2013
Q4 | $484M | Sell |
5,237,455
-443,311
| -8% | -$39.4M | 0.11% | 219 |
|
|
2013
Q3 | $475M | Buy |
5,680,766
+2,248,840
| +66% | +$193M | 0.12% | 219 |
|
|
2013
Q2 | $281M | Buy |
+3,431,926
| New | +$257M | 0.08% | 312 |
|
Other funds holding ELV
VCM
VPM
T. Rowe Price Associates's ELV Position: Q1 2026 in Review
T. Rowe Price Associates reduced its Elevance Health (ELV) stake by 36% in Q1 2026, selling an estimated $887M and leaving 4,746,585 shares worth $1.39B. The position accounts for 0.16% of the portfolio, ranked #125.
T. Rowe Price Associates first reported a position in ELV in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.53B in Q4 2022. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.
- T. Rowe Price Associates held 4,746,585 shares of Elevance Health worth $1.39B as of Q1 2026.
- T. Rowe Price Associates sold 2,699,600 Elevance Health shares in Q1 2026, an estimated $887M.
- Elevance Health made up 0.16% of T. Rowe Price Associates's portfolio in Q1 2026, its #125 holding.
- T. Rowe Price Associates first reported a position in Elevance Health in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Elevance Health position peaked at $6.53B in Q4 2022.
- 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.